4-hydroxy-3-methyl-5-(2-phenylethyl)-2,5-dihydrofuran-2-one



Compound IDCDAMM00073
Common name4-hydroxy-3-methyl-5-(2-phenylethyl)-2,5-dihydrofuran-2-one
IUPAC name3-hydroxy-4-methyl-2-(2-phenylethyl)-2H-furan-5-one
Molecular formulaC13H14O3

Experimental data

Retention time41.34
Adduct[M+H]+
Actual mz219.102
Theoretical mz219.102
Error1.5
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.8868

Identifiers and class information

Inchi keyHVEBVQQBKOIZHU-UHFFFAOYSA-N
SmilesCC1=C(C(OC1=O)CCC2=CC=CC=C2)O
SuperclassOrganoheterocyclic compounds
ClassDihydrofurans

Pharmacokinetic properties

Number of descriptor values(#stars)0
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)4
Number of reactive functional groups (#rtvFG)0
Predicted central nervous system activity (CNS)0
Molecular weight (mol_MW)218.252
Computed dipole moment(dipole)5.861
Total solvent accessible surface area (SASA)472.483
Hydrophobic component of SASA (FOSA)162.804
Hydrophilic component of SASA (FISA)104.905
Pie component of the SASA (PISA)204.774
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)778.718
Number of hydrogen bond donors (donorHB)1
Number of hydrogen bond acceptors (accptHB)3.75
Free energy of solvation of dipole (dip^2/V)0.0441117
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0079368
Globularity descriptor (glob)0.866362
Predicted polarizability in cubic angstroms (QPpolrz)24.397
Predicted hexadecane/gas partition coefficient (QPlogPC16)7.792
Predicted octanol/gas partition coefficient (QPlogPoct)11.666
Predicted water/gas partition coefficient (QPlogPw)7.239
Predicted octanol/water partition coefficient (QPlogPo/w)2.115
Predicted aqueous solubility (QPlogS)-2.948
Conformation-independent predicted aqueous solubility (CIQPlogS)-2.779
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-4.671
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)1002.51
Predicted brain/blood partition coefficient (QPlogBB)-0.609
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)496.054
Predicted skin permeability, log Kp (QPlogKp)-2.347
PM3 calculated ionization potential (IP(ev))9.662
PM3 calculated electron affinity (EA(eV))0.244
Number of likely metabolic reactions (#metab)4
Prediction of binding to human serum albumin (QPlogKhsa)-0.135
Predicted qualitative human oral absorption (HumanOralAbsorption)3
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)93.044
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)61.743
Number of nitrogen and oxygen atoms (#NandO)3
Number of violations of Lipinski’s rule of five (RuleOfFive)0
Number of violations of Jorgensen’s rule of three (RuleOfThree)0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
Q16853AOC3Amine oxidase, copper containingT69619SEA
P15144ANPEPAminopeptidase NT67272SEA
Q96RJ0TAAR1Trace amine-associated receptor 1 (by homology)T99524SEA
Q05940SLC18A2Synaptic vesicular amine transporter (by homology)T48873SEA
Q14832GRM3Metabotropic glutamate receptor 3T02719SEA
P15121AKR1B1Aldose reductaseT26623SEA
P23141CES1Acyl coenzyme A:cholesterol acyltransferaseT76369SEA
P14920DAOD-amino-acid oxidaseT33124SEA
P62942FKBP1AFK506-binding protein 1AT76059SEA
P49286MTNR1BMelatonin receptor 1BT48268SEA
Q16548BCL2A1Bcl-2-related protein A1 (by homology)T12797SEA
Q9NRA0SPHK2Sphingosine kinase 2T31989SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T69619DI0190Hypertension[ICD-11: BA00-BA04]Q16853AOC3
T67272DI0351Psoriasis[ICD-11: EA90]P15144ANPEP
T99524DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]Q96RJ0TAAR1
T99524DI0149Focal/segmental autonomic disorder[ICD-11: 8D8A]Q96RJ0TAAR1
T99524DI0290Narcolepsy[ICD-11: 7A20]Q96RJ0TAAR1
T48873DI0079Choreiform disorder[ICD-11: 8A01]Q05940SLC18A2
T48873DI0125Dissociative neurological symptom disorder[ICD-11: 6B60]Q05940SLC18A2
T48873DI0129Dystonic disorder[ICD-11: 8A02]Q05940SLC18A2
T48873DI0137Essential hypertension[ICD-11: BA00]Q05940SLC18A2
T48873DI0190Hypertension[ICD-11: BA00-BA04]Q05940SLC18A2
T02719DI0370Schizophrenia[ICD-11: 6A20]Q14832GRM3
T26623DI0298Neuropathy[ICD-11: 8C0Z]P15121AKR1B1
T26623DI0366Rheumatoid arthritis[ICD-11: FA20]P15121AKR1B1
T76369DI0335Peroxisomal disease[ICD-11: 5C57]P23141CES1
T76369DI0398Synthesis disorder[ICD-11: 5C52-5C59]P23141CES1
T33124DI0038Ataxic disorder[ICD-11: 8A03]P14920DAO
T33124DI0370Schizophrenia[ICD-11: 6A20]P14920DAO
T76059DI0331Parkinsonism[ICD-11: 8A00]P62942FKBP1A
T76059DI0349Pruritus[ICD-11: EC90]P62942FKBP1A
T76059DI0413Transplant rejection[ICD-11: NE84]P62942FKBP1A
T48268DI0214Insomnia[ICD-11: 7A00-7A0Z]P49286MTNR1B
T31989DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q9NRA0SPHK2

Copyright © 2025